Online citations, reference lists, and bibliographies.
← Back to Search

Malignant Pleural Effusions And Mesothelioma

D. Cooper, T. Peel
Published 2019 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Pleural effusions are a common problem in the palliative phase of a number of different conditions and usually indicate advanced or metastatic disease. They are associated with a significant symptom burden. The investigation of a unilateral pleural effusion starts with ultrasound-guided pleural aspiration, followed if necessary by thoracoscopy or CT-guided biopsy. The recurrent symptomatic effusion can be drained, but without pleurodesis is likely to recur. The options for pleurodesis and the role of indwelling pleural catheters are discussed. The chapter then describes the epidemiology and presenting features of malignant pleural mesothelioma. Management strategies include preventing recurrence of the effusion, symptom control with drugs, and consideration of the appropriateness of chemotherapy. There is rarely a place for surgery. As mesothelioma is ultimately fatal, there is discussion of management in advanced disease and in particular of peritoneal mesothelioma. Medicolegal aspects are also considered.
This paper references
Treatment of malignant pleural effusion: pleurodesis using a small percutaneous catheter. A prospective randomized study.
P. Clementsen (1998)
Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score
A. Clive (2014)
Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial.
H. E. Davies (2012)
Interventions for the management of malignant pleural effusions: a network meta-analysis.
A. Clive (2016)
[Management of malignant pleural effusions].
R. Loddenkemper (2005)
Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant Effusion
R. Bhatnagar (2018)
Etiology and prognostic significance of massive pleural effusions.
D. Jiménez (2005)
Malignant ascites: systematic review and guideline for treatment.
G. Becker (2006)
Pleural fluid pH in malignant effusions. Diagnostic, prognostic, and therapeutic implications.
S. Sahn (1988)
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma
I. Woolhouse (2018)
Evaluating the efficacy of thoracoscopy and talc poudrage versus pleurodesis using talc slurry (TAPPS trial): protocol of an open-label randomised controlled trial
R. Bhatnagar (2014)
Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial.
G. Zalcman (2015)
Prognostic significance of pleural fluid data in patients with malignant effusion.
S. Bielsa (2008)
Population based epidemiology and prognosis of mesothelioma in Leeds, UK
A. Chapman (2008)
Investigating unilateral pleural effusions: the role of cytology
D. Arnold (2018)
A systematic literature review comparing the psychological care needs of patients with mesothelioma and advanced lung cancer.
Hannah L. Ball (2016)
Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion.
C. Dresler (2005)
Important prognostic factors for survival in patients with malignant pleural effusion
M. Zamboni (2015)
Effect of Opioids vs NSAIDs and Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion: The TIME1 Randomized Clinical Trial.
N. Rahman (2015)
A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.
M. O'Brien (2006)
BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations
Marta Cigognetti (2015)
A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis
F. Brims (2016)
Living with mesothelioma. A literature review.
S. Moore (2010)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial.
S. Muruganandan (2018)
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
Living with mesothelioma. A literature review
rn fetc consultant nurse L. Darlison bsc (2009)
Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial
R. Rintoul (2014)
A survey of practice in management of malignant ascites.
C. W. Lee (1998)
Pleural procedures and thoracic ultrasound: British Thoracic Society pleural disease guideline 2010
T. Havelock (2010)
Childhood obstructive sleep apnoea: to treat or not to treat, that is the question
C. Marcus (2010)
Malignant pleural effusions and the role of talc poudrage and talc slurry: a systematic review and meta-analysis
Srinivas R. Mummadi (2014)
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial
Rajesh Thomas (2017)

Semantic Scholar Logo Some data provided by SemanticScholar